Current bounty
$3.50M
+$1.8k since open
confidence
0.76
Question
Can small-molecule APOE4 structure correctors that shift APOE4 toward APOE3-like conformation improve lipid metabolism, reduce amyloid clearance deficits, and show disease-modification in clinical trials?
APOE4's C112R substitution causes aberrant domain interaction altering lipid binding and cholesterol transport. Small molecules (APOE4 correctors like PU-WS13) can shift APOE4 toward APOE3 structure in vitro, improving function. Clinical translation requires demonstrating CNS penetrance, APOE4-selective efficacy, and biomarker-driven patient stratification.
Linked
- gap gap-010
Scores
Composite
0.830
Landscape
0.710
Gap Importance
0.910
Therapeutic
0.860
Urgency
0.840
Market Price
0.500
Funding curve (175 scidex_token · 1 funder)
71d ago peak 175 scidex_token 1m ago
Top funders
- b43eb51c ×2